Drug resistance in pancreatic cancer: New player caught in act.
作者信息
Capurso Gabriele, Sette Claudio
机构信息
PancreatoBiliary Endoscopy and EUS Division, Pancreas Translational and Clinical Research Center, San Raffaele Scientific Institute IRCCS, Milan, Italy.
Institute of Human Anatomy and Cell Biology, Università Cattolica del Sacro Cuore, Rome, Italy; IRCCS Fondazione Santa Lucia, Rome, Italy.
出版信息
EBioMedicine. 2019 Feb;40:39-40. doi: 10.1016/j.ebiom.2019.02.008. Epub 2019 Feb 11.
Abstract
摘要
相似文献
1
Drug resistance in pancreatic cancer: New player caught in act.胰腺癌中的耐药性：新角色被当场抓获。
EBioMedicine. 2019 Feb;40:39-40. doi: 10.1016/j.ebiom.2019.02.008. Epub 2019 Feb 11.
2
Microenvironment in determining chemo-resistance in pancreatic cancer: Neighborhood matters.微环境在决定胰腺癌化疗耐药性中的作用：周围环境很重要。
Pancreatology. 2017 Jan-Feb;17(1):7-12. doi: 10.1016/j.pan.2016.12.010. Epub 2016 Dec 23.
3
Gemcitabine resistance in pancreatic ductal adenocarcinoma.胰腺导管腺癌中的吉西他滨耐药性。
Drug Resist Updat. 2015 Nov;23:55-68. doi: 10.1016/j.drup.2015.10.002. Epub 2015 Nov 3.
4
Targeting the cancer-stroma interaction: a potential approach for pancreatic cancer treatment.靶向肿瘤微环境：胰腺癌治疗的一种潜在方法。
Curr Pharm Des. 2012;18(17):2404-15. doi: 10.2174/13816128112092404.
5
Cancer-associated fibroblasts in pancreatic adenocarcinoma.胰腺腺癌中的癌症相关成纤维细胞
Future Oncol. 2015 Sep;11(18):2603-10. doi: 10.2217/FON.15.176. Epub 2015 Aug 18.
6
Overcoming chemoresistance by targeting reprogrammed metabolism: the Achilles' heel of pancreatic ductal adenocarcinoma.通过靶向重编程代谢克服化疗耐药性：胰腺导管腺癌的阿喀琉斯之踵。
Cell Mol Life Sci. 2021 Jul;78(14):5505-5526. doi: 10.1007/s00018-021-03866-y. Epub 2021 Jun 15.
7
TAMing pancreatic cancer: combat with a double edged sword.TAM 抑制胰腺癌：双刃剑的战斗。
Mol Cancer. 2019 Mar 30;18(1):48. doi: 10.1186/s12943-019-0966-6.
8
Organotypic slice cultures of pancreatic ductal adenocarcinoma preserve the tumor microenvironment and provide a platform for drug response.胰腺导管腺癌的器官型切片培养物保留了肿瘤微环境，并为药物反应提供了一个平台。
Pancreatology. 2018 Dec;18(8):913-927. doi: 10.1016/j.pan.2018.09.009. Epub 2018 Sep 26.
9
Challenges of drug resistance in the management of pancreatic cancer.胰腺癌治疗中药物耐药性的挑战。
Expert Rev Anticancer Ther. 2010 Oct;10(10):1647-61. doi: 10.1586/era.10.148.
10
Overcoming drug resistance in pancreatic cancer.克服胰腺癌的耐药性。
Expert Opin Ther Targets. 2011 Jul;15(7):817-28. doi: 10.1517/14728222.2011.566216. Epub 2011 Mar 11.
引用本文的文献
1
Targeting Hsp70 Immunosuppressive Signaling Axis with Lipid Nanovesicles: A Novel Approach to Treat Pancreatic Cancer.用脂质纳米囊泡靶向热休克蛋白70免疫抑制信号轴：一种治疗胰腺癌的新方法
Cancers (Basel). 2025 Apr 4;17(7):1224. doi: 10.3390/cancers17071224.
2
Exploring the clinical significance of TPX2 in pancreatic cancer: from biomarker to immunotherapy.探索TPX2在胰腺癌中的临床意义：从生物标志物到免疫治疗
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jun;398(6):6843-6864. doi: 10.1007/s00210-024-03628-0. Epub 2024 Dec 17.
3
Targeted delivery of CEBPA-saRNA for the treatment of pancreatic ductal adenocarcinoma by transferrin receptor aptamer decorated tetrahedral framework nucleic acid.转铁蛋白受体适体修饰的四面体核酸载体靶向递送 CEBPA-saRNA 治疗胰腺导管腺癌。
J Nanobiotechnology. 2024 Jul 4;22(1):392. doi: 10.1186/s12951-024-02665-4.
4
Secretory Trefoil Factor 1 (TFF1) promotes gemcitabine resistance through chemokine receptor CXCR4 in Pancreatic Ductal Adenocarcinoma.分泌三叶因子 1（TFF1）通过趋化因子受体 CXCR4 在胰腺导管腺癌中促进吉西他滨耐药。
Cancer Lett. 2024 Aug 28;598:217097. doi: 10.1016/j.canlet.2024.217097. Epub 2024 Jul 2.
5
Integrated bioinformatics analysis reveals upregulated extracellular matrix hub genes in pancreatic cancer: Implications for diagnosis, prognosis, immune infiltration, and therapeutic strategies.整合生物信息学分析揭示胰腺癌中上调的细胞外基质枢纽基因：对诊断、预后、免疫浸润和治疗策略的影响。
Cancer Rep (Hoboken). 2024 Apr;7(4):e2059. doi: 10.1002/cnr2.2059.
6
Roles of microbiota in pancreatic cancer development and treatment.微生物群在胰腺癌发生和治疗中的作用。
Gut Microbes. 2024 Jan-Dec;16(1):2320280. doi: 10.1080/19490976.2024.2320280. Epub 2024 Feb 27.
7
Nanoparticle-Mediated Therapy with miR-198 Sensitizes Pancreatic Cancer to Gemcitabine Treatment through Downregulation of VCP-Mediated Autophagy.纳米颗粒介导的miR-198疗法通过下调VCP介导的自噬使胰腺癌对吉西他滨治疗敏感。
Pharmaceutics. 2023 Jul 28;15(8):2038. doi: 10.3390/pharmaceutics15082038.
8
Counteracting gemcitabine+nab-paclitaxel induced dysbiosis in KRAS wild type and KRAS mutated pancreatic cancer in vivo model.在KRAS野生型和KRAS突变型胰腺癌体内模型中对抗吉西他滨+纳米白蛋白结合型紫杉醇诱导的菌群失调
Cell Death Discov. 2023 Apr 5;9(1):116. doi: 10.1038/s41420-023-01397-y.
9
New Insights into the Biological Response Triggered by Dextran-Coated Maghemite Nanoparticles in Pancreatic Cancer Cells and Their Potential for Theranostic Applications.葡聚糖包覆的磁赤铁矿纳米颗粒在胰腺癌细胞中引发的生物学反应的新见解及其在治疗应用中的潜力。
Int J Mol Sci. 2023 Feb 7;24(4):3307. doi: 10.3390/ijms24043307.
10
Culprits of PDAC resistance to gemcitabine and immune checkpoint inhibitor: Tumour microenvironment components.胰腺癌对吉西他滨和免疫检查点抑制剂耐药的原因：肿瘤微环境成分。
Front Mol Biosci. 2022 Oct 10;9:1020888. doi: 10.3389/fmolb.2022.1020888. eCollection 2022.
本文引用的文献
1
Cytosolic 5'-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites.细胞质 5'-核苷酸酶 1A 在胰腺癌中过表达，并通过降低细胞内吉西他滨代谢物来介导吉西他滨耐药性。
EBioMedicine. 2019 Feb;40:394-405. doi: 10.1016/j.ebiom.2019.01.037. Epub 2019 Jan 30.
2
Systemic treatment of pancreatic cancer revisited.胰腺癌的系统治疗再探。
Semin Oncol. 2019 Feb;46(1):28-38. doi: 10.1053/j.seminoncol.2018.12.003. Epub 2018 Dec 27.
3
Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe.欧洲临床常规中强化化疗对转移性胰腺导管腺癌（PDAC）的影响。
Pancreatology. 2019 Jan;19(1):97-104. doi: 10.1016/j.pan.2018.10.003. Epub 2018 Oct 15.
4
Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial.白蛋白结合型紫杉醇联合吉西他滨加或不加卡培他滨和顺铂治疗转移性胰腺导管腺癌（PACT-19）：一项随机 2 期试验。
Lancet Gastroenterol Hepatol. 2018 Oct;3(10):691-697. doi: 10.1016/S2468-1253(18)30196-1. Epub 2018 Jul 7.
5
Pancreatic cancer stem cells: A state or an entity?胰腺癌干细胞：一种状态还是一种实体？
Semin Cancer Biol. 2018 Dec;53:223-231. doi: 10.1016/j.semcancer.2018.08.007. Epub 2018 Aug 18.
6
Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death.吉西他滨和 nab-紫杉醇联合治疗对胰腺癌细胞死亡具有相加作用。
Oncol Rep. 2018 Apr;39(4):1984-1990. doi: 10.3892/or.2018.6233. Epub 2018 Jan 25.
7
Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.预计 2030 年美国癌症发病与死亡人数：甲状腺癌、肝癌和胰腺癌带来的意外负担。
Cancer Res. 2014 Jun 1;74(11):2913-21. doi: 10.1158/0008-5472.CAN-14-0155.
8
Biology and management of pancreatic cancer.胰腺癌的生物学特性与管理
Gut. 2007 Aug;56(8):1134-52. doi: 10.1136/gut.2006.103333.
Zotero 插件